This is the classic website, which will be retired eventually. Please visit the modernized ClinicalTrials.gov instead.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT05862324
Previous Study | Return to List | Next Study

TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3) (TACTIC-3)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05862324
Recruitment Status : Recruiting
First Posted : May 17, 2023
Last Update Posted : April 22, 2024
Sponsor:
Information provided by (Responsible Party):
Triumvira Immunologics, Inc.

Brief Summary:

TAC01-CLDN18.2 is a novel cell therapy that consists of genetically engineered autologous T cells expressing T-cell Antigen Coupler (TAC) that recognizes Claudin 18.2. TAC directs T-cells to the targeted antigen (CLDN 18.2), and once engaged with the target, activates them via the endogenous T cell receptor.

This is an open-label, multicenter Phase ½ study that aims to establish safety, maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D), pharmacokinetic profile and efficacy of TAC01-CLDN18.2.


Condition or disease Intervention/treatment Phase
Metastatic Solid Tumor Biological: TAC01-CLDN18.2 Phase 1 Phase 2

Detailed Description:

The TAC technology is a novel approach to modifying T cells, herein referred to as TAC T cells, and using them in the treatment of solid tumors. TAC T cells are produced through genetic engineering, incorporating TAC receptors into a patient's own T cells. This redirects these enhanced T cells to specific cancer antigens, and upon recognition, activates them through the natural signaling pathways of the endogenous TCR.

In the TAC01-CLDN18.2 engineered T cell product; TAC T cells recognize the CLDN18.2, a tight junction protein present on the surface of tumor cells, where the protein expression is no longer limited to tight junctions and are visible to T cells to eradicate them. Consequently, it is hypothesized TAC01-CLDN18.2 will be potentially safe and active in treating patients with CLDN18.2+ solid tumors and provide a clinically meaningful therapeutic benefit in patient populations with high unmet medical need.

This is a first-in-human study investigating TAC01-CLDN18.2 to evaluate the safety, MTD or RP2D, PK, and efficacy in subjects with CLDN18.2+ solid tumors who have been treated with at least 2 lines of prior therapy in Phase 1 and after at least 2 lines and no more than 4 lines of prior therapy in Phase 2 (Note: in each phase, subjects with PDAC may have been treated with 1 line of prior antineoplastic therapy. In addition, subjects who are being treated with current lines of therapy, but not deriving benefit or not tolerating therapy, and have not progressed maybe also eligible as long as they have measurable disease at baseline as a starting reference point). In Phase 1, escalating doses of TAC01-CLDN18.2 will be evaluated to identify the RP2D using the classic 3+3 dose escalation study design.

In Phase 2, dose expansion groups will further evaluate the efficacy, safety, and PK of the MTD or RP2D for TAC01-CLDN18.2 in subjects with gastric and esophageal AC (Group A), PDAC (Group B), and mucinous ovarian and NSCLC cancers (Group C). In Phase 2, definitions of eligible CLDN18.2+ IHC expression levels will be based on analysis of data from Phase 1 for signals of clinical activity since there are no formal CAP/ASCO guidelines for CLDN18.2+ expression levels. In Phase 2, a Simon 2-stage design will be used to enroll up to 57 subjects in Group A and 22 subjects in Group C. Group B (PDAC) will enroll up to 10 subjects as an exploratory cohort due to the historically low ORRs observed in PDAC. The 10 treated subjects in Group B are designed to seek evidence of potential clinical activity in this difficult to treat CLDN18.2+ subpopulation of PDAC.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 113 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: In Phase 1, escalating doses of TAC01-CLDN18.2 will be evaluated to identify the RP2D using the classic 3+3 dose escalation study design. In Phase 2, dose expansion groups will further evaluate the safety, efficacy, and PK of the MTD or RP2D for TAC01-CLDN18.2 in subjects with gastric and esophageal AC (Group A), PDAC (Group B), and ovarian and NSCLC cancers (Group C). In Phase 2, definitions of eligible CLDN18.2+ IHC expression levels will be based on retrospective analysis of data from Phase 1 in association with clinical efficacy because there are no formal CAP/ASCO definitions for CLDN18.2+ IHC expression levels. In Phase 2, a Simon 2-stage design will be used to enroll up to 57 subjects in Group A and 22 subjects in Group C. Group B will enroll up to 10 subjects without a Simon 2-stage design due to its historically low ORRs. The 10 treated subjects in Group B are designed to seek evidence of potential efficacy in this difficult to treat CLDN18.2+ subpopulation of PDAC.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1/2 Study Investigating the Safety and Efficacy of Autologous TAC T Cells in Subjects With Unresectable, Locally Advanced or Metastatic Claudin 18.2+ Solid Tumors
Actual Study Start Date : August 23, 2023
Estimated Primary Completion Date : August 1, 2027
Estimated Study Completion Date : August 1, 2027

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: TAC01-CLDN18.2
Lymphodepletion followed by TAC01-CLDN18.2 as a single IV infusion.
Biological: TAC01-CLDN18.2
TAC01-CLDN18.2 preceded by lymphodepletion with fludarabine or clofarabine, cyclophosphamide, and nab-paclitaxel.




Primary Outcome Measures :
  1. Phase 1: Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability) [ Time Frame: 24 Months ]
    Document incidence of DLTs; Type, frequency, and severity of AEs (including clinically significant laboratory abnormalities).

  2. Phase 2: Evaluate Overall Response Rate (ORR) [ Time Frame: 24 Months ]
    Defined as the percentage of treated subjects with a complete or partial response (CR or PR) as assessed by imaging using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1

  3. Phase 2: Evaluate Duration of Response (DoR) [ Time Frame: 24 Months ]
    Defined as time from first response to disease progression, end of study, start of another anticancer therapy, or death.

  4. Phase 2: Evaluate Overall survival (OS) [ Time Frame: 24 Months ]
    Defined as time from infusion to death from any cause.

  5. Phase 2: Evaluate Disease control rate (DCR) [ Time Frame: 24 Months ]
    Defined as the percentage of treated subjects with stable disease (SD), PR, and CR as assessed by imaging using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1.

  6. Phase 2: Evaluate Progression-Free survival (PFS) or Time to progression (TTP) [ Time Frame: 24 Months ]
    Defined as time from infusion to disease progression or death from any cause.


Secondary Outcome Measures :
  1. Phase 1: Determine MTD or RP2D for TAC01-CLDN 18.2 [ Time Frame: Up to 29 Days Post TAC01-CLDN18.2 infusion ]
    Document incidence of Dose-Limiting Toxicities.

  2. Phase 1: Evaluate Overall Response Rate (ORR) [ Time Frame: 24 months ]
    Defined as the percentage of treated subjects with a complete or partial response (CR or PR) as assessed by imaging using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1.

  3. Phase 1: Evaluate Duration of Response (DoR) [ Time Frame: 24 Months ]
    Defined as time from first response to disease progression, end of study, start of another anticancer therapy, or death.

  4. Phase 1: Evaluate Overall survival (OS) [ Time Frame: 24 Months ]
    Defined as time from infusion to death from any cause. Duration of persistence of TAC T cells

  5. Phase 1: Evaluate Disease control rate (DCR) [ Time Frame: 24 Months ]
    Defined as the percentage of treated subjects with stable disease (SD), PR, and CR as assessed by imaging using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1.

  6. Phase 1: Evaluate Progression-Free survival (PFS) or Time to progression (TTP) [ Time Frame: 24 Months ]
    Defined as time from infusion to disease progression or death from any cause.

  7. Phase 2: Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability). [ Time Frame: 24 Months ]
    Document type, frequency, and severity of AEs (including clinically significant laboratory abnormalities).


Other Outcome Measures:
  1. Phase 1 and Phase 2: Cmax of TAC01-CLDN18.2 (pharmacokinetics; PK). [ Time Frame: 24 Months ]

    Defined as the maximum concentration of TAC T cells after infusion; assessed by vector copy number.

    Describe profile of soluble immune factors and relationship to cytokine release syndrome (CRS), neurotoxicity, and TAC T cell engraftment


  2. Phase 1 and Phase 2: Tmax of TAC01-CLDN18.2 (PK) [ Time Frame: 24 Months ]
    Defined as the first study day the Cmax is reached; assessed by vector copy number.

  3. Phase 1 and Phase 2: area under the concentration time curve (AUC) of TAC01-CLDN18.2 (PK) [ Time Frame: 24 Months ]
    Calculated using the trapezoid rule; assessed by vector copy number.

  4. Phase 1 and Phase 2: Duration of persistence of TAC T cells (PK) [ Time Frame: 24 Months ]
    Defined as the time between the first measurement of transgene above the limit of detection until the last observed quantifiable level of transgene; assessed by vector copy number.

  5. Phase 1 and Phase 2: Human anti-mouse antibody (HAMA) detection. [ Time Frame: 24 Months ]
    Correlation of HAMA detection with TAC PK and subject response

  6. Phase 1 and Phase 2: Cytokine level detection [ Time Frame: 24 Months ]
    Correlation with adverse events and subject response

  7. Phase 1 and Phase 2: Product manufacturing feasibility/success [ Time Frame: Duration of the study ]
    Number of successful manufacturing of TAC01-CLDN18.2 products per subject leukapheresis samples.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Signed, written informed consent obtained before any study procedures are conducted.
  2. Age ≥ 18 years at the time of informed consent.
  3. Tumor tissue samples positive for CLDN18.2 as assessed by central laboratory and HER2 expression negative.
  4. Histologically confirmed advanced, metastatic, unresectable CLDN18.2+ solid tumors after at least 2 lines of prior therapy (Phase 1) and after at least 2 and no more than 4 prior lines of therapy (Phase 2). Subjects with PDAC may have been treated with 1 line of prior therapy.

    1. Subjects with incurable Claudin 18.2 expressing malignancies for which no standard-of-care targeted therapy exists may be enrolled regardless of the number of prior treatment lines.
    2. Specific Phase 1 tumor types include gastric, GEJ, esophageal adenocarcinoma, PDAC, colorectal cancer, cholangiocarcinoma, ovarian mucinous cancer, gallbladder cancer and NSCLC.
    3. Specific Phase 2 tumor types include gastric and esophageal adenocarcinoma (Group A), PDAC (Group B), and ovarian or NSCLC (Group C). Other tumor types are not eligible.
  5. Subjects with solid tumors with genetic alterations and mutations (e.g., BRAF, BRCA, EGFR mutations, and ALK translocation) where approved targeted therapies were available to their specific cancers must have been previously treated with such approved therapies, or refused such approved targeted therapy for their cancers, prior to enrollment, or in the opinion of the Investigator would be unlikely to tolerate or derive clinically meaningful benefit from these standard-of-care therapies.
  6. Measurable disease per RECIST 1.1 at time of enrollment.
  7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at Screening.
  8. Life expectancy of at least 12 weeks.
  9. Adequate organ and bone marrow reserve function prior to leukapheresis as outlined in protocol.
  10. Recovery to Grade ≤ 1 or baseline for any toxicities due to previous therapy, except alopecia, anemia, thrombocytopenia, neutropenia, and neuropathy.

    1. If a subject received major surgery, they must have recovered from the procedure and/or any complications from the procedure prior to starting TAC01-CLDN18.2 therapy.
    2. Toxicity that has not recovered to Grade ≤ 1 is allowed if it meets the inclusion requirements for laboratory parameters.
  11. Adequate vascular access for leukapheresis as per institutional standards
  12. For women physiologically capable of becoming pregnant, agreement to use highly effective methods of contraception starting 28 days prior to study treatment and continue for 1 year after the last TAC01-CLDN18.2 infusion. For men who have partners physiologically capable of becoming pregnant, agreement to use an effective barrier contraceptive method and refrain from donating sperm during study treatment and for 1 year after the last TAC01-CLDN18.2 infusion.
  13. Subjects who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load prior to enrollment. Note: Subjects should remain on antiviral therapy throughout study intervention and follow local guidelines for HBV antiviral therapy post completion of study intervention.
  14. Subjects with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at Screening. Note: Subjects must have completed curative antiviral therapy at least 4 weeks prior to enrollment.

Exclusion Criteria:

  1. Intolerant to any component of TAC01-CLDN18.2
  2. Prior treatment with any of the following:

    1. Adoptive cell transfer of any kind, including CAR T cells.
    2. Gene therapy
  3. Prior treatment with a CLDN18.2 targeted agent (Phase 2 only)
  4. Investigational medicinal product within 5 half-lives or 21 days prior to leukapheresis, whichever is shorter.
  5. Participation in or has participated in a study using an investigational device within 4 weeks prior to the first dose of study treatment.
  6. Receipt of a live or live-attenuated vaccine within 30 days prior to the first dose of study Intervention. Administration of killed vaccines are allowed.
  7. Radiation within 28 days prior to leukapheresis. Palliative radiation is allowed up to 14 days prior to leukapheresis if additional non-irradiated lesions are present.
  8. Chemotherapy or targeted small molecule therapy within 14 days prior to leukapheresis, or within 7 days prior to leukapheresis for erlotinib, gefitinib, afatinib, or crizotinib in NSCLC subjects.
  9. Colony stimulating factors, including granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), erythropoietin, and other hematopoietic cytokines, within 14 days prior to leukapheresis.
  10. Immunosuppressive medication within 14 days or corticosteroid treatment < 72 hours prior to leukapheresis, except for physiological replacement doses (< 12 mg/m2/24 hours of hydrocortisone or equivalent) and topical or inhaled steroids.
  11. History or presence of clinically relevant central nervous system (CNS) pathology such as epilepsy, seizure, paresis, aphasia, stroke, severe brain injury, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or psychosis.
  12. Known active CNS metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable, i.e., without evidence of progression for at least 4 weeks by repeat imaging (note that the repeat imaging should be performed during study Screening), clinically stable and without requirement of steroid treatment for at least 14 days prior to first dose of study treatment.
  13. Active inflammatory neurological disorders (e.g., Guillain-Barre Syndrome, amyotrophic lateral sclerosis, multiple sclerosis).
  14. Active autoimmune disease (e.g., lupus, rheumatoid arthritis, Sjogren's syndrome) requiring systemic disease modifying agents in the past 2 years. Hormone replacement therapy (e.g., thyroxine, insulin), or physiologic corticosteroid replacement therapy (for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
  15. Active or uncontrolled hepatitis B or C (HCV ribonucleic acid [RNA] positive) infection or any history of or active human immunodeficiency virus (HIV) infection.
  16. Uncontrolled, acute, or life-threatening bacterial, viral, or fungal infection. Subjects with ongoing use of prophylactic antibiotics, antifungals, or antivirals are eligible if there is no evidence of active infection (includes COVID positive subjects).
  17. Class III or IV heart failure (as defined by the New York Heart Association [NYHA]), cardiac angioplasty or stenting, myocardial infarction, unstable angina, or other clinically significant cardiac disease within 6 months prior to Screening.
  18. Cardiac arrhythmia not controlled by medical management.
  19. Clinically significant thrombotic events within 3 months prior to leukapheresis and/or inability to stop anticoagulation for at least 2 weeks prior to TAC01-CLDN18.2 infusion without compromising a subject's health (except in subjects with PDAC).
  20. Prior radiation therapy to the lung > 30 Gy within 6 months of the first dose of study treatment.
  21. History of Grade ≥ 3 drug-induced pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease.
  22. Ongoing unstable or active gastrointestinal ulcers and gastrointestinal bleeding.
  23. Complete gastric outlet syndrome or a partial gastric outlet syndrome with persistent/recurrent vomiting.
  24. History of organ transplantation or awaiting organ transplantation.
  25. Known additional malignancy that is progressing or requires active treatment or has been an incurable malignant tumor over the last 5 years. Exceptions include basal cell carcinoma of the skin, non-metastatic squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy.
  26. Pregnancy or lactation. Females physiologically capable of becoming pregnant must have a negative serum beta human chorionic gonadotropin (β-hCG) pregnancy test result at Screening and within 48 hours prior to the first dose of LDC.
  27. As determined by the Investigator, any uncontrolled medical, psychological, familial, sociological, or geographical condition(s) that do(es) not permit compliance with the protocol.
  28. Has a known psychiatric or any disorder that would interfere with the participant's ability to cooperate with the requirements of the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05862324


Contacts
Layout table for location contacts
Contact: Kara M Moss 512-953-2290 patient.info@triumvira.com

Locations
Layout table for location information
United States, California
University of Southern California Recruiting
Los Angeles, California, United States, 90033
Contact: Xiomara Menendez       Xiomara.Menendez@med.usc.edu   
Contact: Lorraine Martinez       Lorraine.Martinez@med.usc.edu   
Principal Investigator: Syma Iqbal, MD         
University of California San Diego Recruiting
San Diego, California, United States, 92037
Contact: Gregory Botta, MD, PhD    844-317-7836    alphastemcellclinic@health.ucsd.edu   
Principal Investigator: Gregory Botta, MD, PhD         
United States, Ohio
Cincinnati Cancer Center Recruiting
Cincinnati, Ohio, United States, 45267
Contact: Davendra Sohal, MD       cancer@uchealth.com   
Principal Investigator: Davendra Sohal, MD         
United States, Texas
MD Anderson Cancer Center Recruiting
Houston, Texas, United States, 77030
Contact: Miriam Gavriliuc       mngavriliuc@mdanderson.org   
Principal Investigator: Ecaterina Dumbrava, MD         
Canada, Quebec
Centre hospitalier de l'Université de Montréal Recruiting
Montréal, Quebec, Canada, H2X 0C1
Contact: Simon Turcotte, MD    514-890-8000 ext 30737    uit.eligibilite.chum@ssss.gouv.qc.ca   
Principal Investigator: Simon Turcotte, MD         
Sponsors and Collaborators
Triumvira Immunologics, Inc.
Layout table for additonal information
Responsible Party: Triumvira Immunologics, Inc.
ClinicalTrials.gov Identifier: NCT05862324    
Other Study ID Numbers: TAC01-CLDN18.2-04
First Posted: May 17, 2023    Key Record Dates
Last Update Posted: April 22, 2024
Last Verified: February 2024
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Triumvira Immunologics, Inc.:
Claudin 18.2, Claudin+, Claudin Positive
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms